Clinical Trial Update: Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy, safety, and tolerability of E2027 (Irsenontrine) in participants with Dementia with Lewy Bodies has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia with Lewy Bodies

Drugs mentioned

• E2027 (Hereinafter Referred to as Irsenontrine) (Irsenontrine)

Snippet

Sponsor: Eisai Inc. | Conditions: Dementia With Lewy Bodies | Phase 2 | Status: COMPLETED | Results posted: 2022-08-01